Protocol Ledger

NCT05639647 · Phase II · RECRUITING

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Interventional Phase II clinical trial protocol NCT05639647 sponsored by Pfizer in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-18 Enrollment: 48 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05639647
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05639647
Protocol FieldVerified Registry Value
NCT IdentifierNCT05639647
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment48 participants (ESTIMATED)
Registered Start Date2023-04-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI